Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-ATLAS-III: ctDNA MRD-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer
NCT07508956Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Disease-Free Survival up to 3 years. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07508956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508956.